GlassScriptPhysician profile
Erin T Pratt
NPI 1124297627
$16,756.24
in general payments reported to CMS, 2019-2025
43 companies · $3,335 in 2025
The $3,335 reported for 2025 was more than what 78% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,334 · 2020: $1,191 · 2021: $1,994 · 2022: $2,469 · 2023: $2,378 · 2024: $4,055 · 2025: $3,335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,413 · Consulting Fee: $1,201 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,413.31 |
| Consulting Fee | $1,201.14 |
| Education | $153.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $2,727.17 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,012.73 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Pfizer INC. | $1,597.32 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,473.65 | 2019-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $1,443.05 | 2019-2025 | Dupixent |
| Csl Behring | $1,083.36 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Grifols USA, LLC | $810.51 | 2019-2025 | Xembify |
| Amgen INC. | $704.31 | 2021-2025 | Actimmune, Tezspire |
| Pharming Healthcare, INC. | $619.50 | 2020-2025 | Ruconest, Joenja |
| Takeda Pharmaceuticals U.S.A., INC. | $567.91 | 2021-2025 | Cuvitru, Eohilia, Takhzyro |
| Adma Biomanufacturing LLC | $507.93 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $352.51 | 2019-2025 | |
| Biocryst US Sales Co., LLC | $317.06 | 2021-2025 | Orladeyo |
| Incyte Corporation | $313.51 | 2021-2025 | Opzelura |
| Octapharma USA, INC. | $300.70 | 2019-2024 | Octagam Immune Globulin (Human) |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.